Proposed QIBA SPECT Biomarker Committee (BC)
Friday, February 20, 2015, 9 AM (CT)
Draft Call Summary

In attendance:
Richard Wahl, MD (Moderator)  Adriaan Lammertsma, PhD  Anne M. Smith, PhD  RSNA
Ronald Boellaard, PhD  Michael Lassman, PhD  Eli Stern, BSc, MBA  Fiona Miller
Janice Campbell, PhD  William C. (Rusty) Lavel, MD  John Strologas, PhD  Joe Koudelik
Ming-Kai Chen, MD, PhD  Martin Lodge, PhD  John Sunderland, PhD
Yuni Dewaraja, PhD  Manuela Matesan, MD, PhD  Pierre Tervé, MS
Eric Frey, PhD  Robert Miyaoka, PhD  Benjamin Tsui, PhD
John Hoffman, MD  P. David Mozley, MD  Timothy Turkington, PhD
Paul Kinahan, PhD, FIEEE  Aaron Nelson, MD  Wolfgang Weber, MD
Michael King, PhD, DABR  Dennis Nelson, PhD  Scott Wollenweber, PhD
Gregory Klein, PhD  Eric Perlman, MD  John Wolodzko, PhD
Richard Laforest, PhD  John Seibyl, MD  Brian Zimmerman, PhD

Moderator: Dr. Richard Wahl

Discussion
- Joint meeting with the QIBA FDG-PET/CT Biomarker Committee members began with a brief update on the NIBIB March 2015 Progress Report; BC leaders to draft brief two paragraph status reports for Mr. Buckler (by Feb 27th) for incorporation into a larger QIBA semi-annual progress report as required by our federal NIBIB contract
  - Reminder to Round-3 project PIs to submit their final project reports by the end of February
  - Round-3 PI final project reports are needed to close Rnd-3 projects and may also be used to supplement the NIBIB semi-annual report
- A SPECT Profile was suggested with both a technical and clinical focus; suggested organ systems included:
  - Peptide therapy for kidney
  - Selection of an isotope: lutetium (Lu), or technetium (Tc)
  - Bone quantitation
  - Heart
  - Absolute organ uptake
  - DaTscan vs. organ – radiation dosimetry
- The group plans to begin with a gap analysis and discussion of data for testing potential Profile claims, led by Dr. Seibyl.
  - A simple use case with a strong clinical claim is needed
  - SPECT parameters suggested:
    - Parameters with low bias, good precision, and relative reproducibility deemed important
    - Consideration for future innovators, with respect to how they approach solutions, particularly on the device side, is also very important
    - Innovation encouraged without excessive prescription in the Profile
- Dr. Seibyl to identify some relevant datasets for discussion on the next call

Upcoming Nuclear Medicine Calls (Fridays, 9 am CT):
- February 26  PET Amyloid: Site Qualification Task Force
- February 27  PET Amyloid: Image Analysis Task Force (in place of Amyloid Biomarker Ctte)
- March 06  FDG-PET Biomarker Ctte – UPICT FDG-PET/CT Protocol Discussion (led by Dr. Graham)
- March 13  PET Amyloid Biomarker Ctte
- March 20  SPECT Task Force
- March 27  PET Amyloid Biomarker Ctte
- April 3  FDG-PET Biomarker Ctte

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries. QIBA wiki